Ortho Clinical Diagnostics Presents Cardiac Advances at EuroMedLab 2019
|
By LabMedica International staff writers Posted on 20 May 2019 |

Image: The Multi-Test VITROS chemistry product slides (Photo courtesy of Ortho Clinical Diagnostics).
Ortho Clinical Diagnostics (Raritan, NJ, USA) sponsored an educational workshop on high-sensitivity troponin assays and presented five scientific posters at EuroMedLab 2019, the 23rd IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine, which took place from May 19-23, 2019, at the CCIB - Centre Convencions Internacional in Barcelona. Ortho also displayed its new multi-test VITROS Chemistry Product Slides, the VITROS Cell, a compact automation solution allowing two VITROS XT 7600 instruments (launched in 2018) to operate as a seamless solution, and the VITROS XT 7600 Integrated System at its booth during the congress.
Ortho, an in vitro diagnostics company serving the clinical laboratory and immunohematology communities, offers sophisticated testing technologies, automation, information management and interpretation tools to clinical laboratories around the world to help them run more efficiently and effectively and improve patient care. Ortho's high-quality products and services enable health care professionals to make better-informed treatment decisions across hospitals, hospital networks, blood banks and labs in more than 125 countries and territories.
In addition to the educational workshop, "The Clinical Use and Performance of High-Sensitivity Troponin Assays with the Esc 0-1 Algorithm: Overcoming Challenges in Implementation," Ortho presented the following five scientific posters at EuroMedLab:
- Evaluation of the New Multi-Test VITROS Chemistry Product Slides on the VITROS XT 7600 Integrated System
- Sigma Metrics for Assessing the Analytical Quality of the New Multi-Test VITROS XT Chemistry Products Slides
- Precision of the New Multi-Test VITROS Chemistry Product Slides on the VITROS XT 7600 Integrated System
- Performance Evaluation of the VITROS hs Troponin I Assay on the VITROS ECi/ECiQ and 3600 Immunodiagnostic and VITROS 5600/XT 7600 Integrated Systems
- Performance Evaluation of the VITROS Immunodiagnostic Products B·R·A·H·M·S PCT Assay on the VITROS 3600 Immunodiagnostic System
"Ortho is committed to staying ahead of the rapidly evolving clinical lab environment," said Joan Martin, executive vice president and head of Ortho's EMEA region." At this year's EuroMedLab, we're proud to be presenting data on two of our just-launched, key product offerings: our new high-sensitivity troponin assay and Ortho's VITROS XT MicroSlide. The XT MicroSlide can perform two tests simultaneously to improve lab workflow performance, productivity and clinical outcomes."
Ortho, an in vitro diagnostics company serving the clinical laboratory and immunohematology communities, offers sophisticated testing technologies, automation, information management and interpretation tools to clinical laboratories around the world to help them run more efficiently and effectively and improve patient care. Ortho's high-quality products and services enable health care professionals to make better-informed treatment decisions across hospitals, hospital networks, blood banks and labs in more than 125 countries and territories.
In addition to the educational workshop, "The Clinical Use and Performance of High-Sensitivity Troponin Assays with the Esc 0-1 Algorithm: Overcoming Challenges in Implementation," Ortho presented the following five scientific posters at EuroMedLab:
- Evaluation of the New Multi-Test VITROS Chemistry Product Slides on the VITROS XT 7600 Integrated System
- Sigma Metrics for Assessing the Analytical Quality of the New Multi-Test VITROS XT Chemistry Products Slides
- Precision of the New Multi-Test VITROS Chemistry Product Slides on the VITROS XT 7600 Integrated System
- Performance Evaluation of the VITROS hs Troponin I Assay on the VITROS ECi/ECiQ and 3600 Immunodiagnostic and VITROS 5600/XT 7600 Integrated Systems
- Performance Evaluation of the VITROS Immunodiagnostic Products B·R·A·H·M·S PCT Assay on the VITROS 3600 Immunodiagnostic System
"Ortho is committed to staying ahead of the rapidly evolving clinical lab environment," said Joan Martin, executive vice president and head of Ortho's EMEA region." At this year's EuroMedLab, we're proud to be presenting data on two of our just-launched, key product offerings: our new high-sensitivity troponin assay and Ortho's VITROS XT MicroSlide. The XT MicroSlide can perform two tests simultaneously to improve lab workflow performance, productivity and clinical outcomes."
Latest Industry News
- Qiagen Agrees to Go Private Through EQT-Led Acquisition
- Hologic and Inpeco Partner to Advance Molecular Laboratory Automation in Europe
- Collaboration to Expand Cervical Cancer Screening Access With At-Home HPV Collection
- Myriad Genetics to Sell Prenatal Testing Portfolio to Labcorp
- Alzheimer’s Progression Blood Test Gains U.S. Patent Ahead of Planned Launch
- Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition
- Labcorp Acquisition to Strengthen Specialty Testing and Prostate Cancer Assessment
- Collaboration Advances Genomic Instability Biomarker for Prostate Cancer
- Managed Care Report Examines Barriers to Breast Cancer Biomarker Testing
- Expanding Screening and Biomarker Testing Drive Cancer Diagnostics Market Growth
- Expanded Partnership Scales AI-Powered Digital Pathology for Oncology
- Hospital Partnership Advances Clinical Validation of Portable Diagnostic Technology
- Diazyme Expands Chemistry Testing Portfolio With Alfa Wassermann Acquisition
- Global TB Summit Connects Diagnostic Testing With Prevention and Clinical Care
- Agilent's Acquisition of Proscia to Advance AI-Enabled Digital Pathology Workflows
- Digital Pathology Collaboration Expands Laboratory Access to AI-Driven Diagnostics
Channels
Clinical Chemistry
view channel
Point-of-Care Blood Biomarker Test Detects Brain Injury Missed by CT
Traumatic brain injury remains difficult to assess in emergency settings because some patients continue to have symptoms despite normal computed tomography findings. Approximately 2.8 million people in the U.... Read more
Daily Blood Testing May Help Guide Earlier Antibiotic Stopping in Sepsis
Sepsis is a life-threatening condition caused by the body’s overwhelming response to infection and accounts for thousands of deaths each year. In intensive care, concern about stopping treatment too early... Read moreMolecular Diagnostics
view channel
Molecular Vaginitis Panel Gains FDA Clearance and CLIA Waiver for Point-of-Care Use
Vaginitis affects most women at least once in their lifetime and can cause painful, disruptive symptoms. Common causes include bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis, reflecting... Read more
AI Tool Predicts Immunotherapy Response Using Tumor Senescence Signals
Patients receiving the same cancer immunotherapy can have markedly different outcomes, with some showing little or no response. Identifying these patients earlier could reduce the costs of ineffective... Read moreHematology
view channel
New Myelofibrosis Guidelines Recommend Expanded Genetic Testing at Diagnosis
Myelofibrosis is a rare, life-threatening blood cancer affecting up to six per 100,000 people. The disease causes scarring in the bone marrow, limiting the production of healthy blood cells and potentially... Read more
Handheld Point-of-Care Test Aims to Enable Rapid Coagulation Assessment in Trauma
Severe blood loss and inadequate tissue oxygenation are leading causes of preventable death after traumatic injury. Blood products are essential in trauma care, but cold-chain storage, short shelf life,... Read moreImmunology
view channel
Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more
Immune Profiling Initiative Aims to Improve Bone Marrow Analysis in Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer in which assessing disease burden after therapy can help guide clinical evaluation. Patients with measurable residual disease (MRD) after treatment... Read more
Immune Profiling Identifies Early Maternal Autoantibodies Linked to Preterm Birth Risk
A typical pregnancy lasts about 40 weeks, but labor begins prematurely in roughly one in 10 pregnancies. Preterm birth is the leading cause of newborn death worldwide, yet its underlying causes and which... Read more
Longitudinal Blood Testing Reveals Changes in Allergen Sensitization During Childhood
Food allergy is a major childhood health concern, and distinguishing persistent risk from transient sensitization can guide clinical decisions. Specific IgE antibodies may be detectable even when a child... Read moreMicrobiology
view channel
Molecular Panel Gains WHO Emergency Use Listing to Support Ebola Outbreak Response
The ongoing Ebola Bundibugyo outbreak in the Democratic Republic of the Congo and neighboring countries has become one of the largest outbreaks of this Ebola virus species recorded to date.... Read more
Rapid Host-Response Test Aims to Predict Corticosteroid Benefit in Sepsis
Sepsis and severe infections are difficult to treat because patients with similar clinical presentations may have very different underlying immune responses. Corticosteroids are commonly used in severe... Read morePathology
view channel
Digital Pathology Test Stratifies Recurrence Risk in Early Breast Cancer
In hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer, accurate recurrence-risk assessment helps guide treatment decisions. However, individual risks... Read more
AI Pathology Tool Predicts DNA Repair Deficiency in High-Grade Serous Ovarian Cancer
High-grade serous tubo-ovarian carcinoma is an aggressive cancer arising in the ovaries or fallopian tubes. Some tumors exhibit homologous recombination deficiency (HRD), a feature reflecting impaired DNA repair.... Read moreTechnology
view channel







